Last reviewed · How we verify
Localization-related epilepsy
Approved treatments
- Phenytoin Sodium · Viatris
Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation. - Tegretol · Novartis AG (originally Geigy)
Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain. - Carbamazepin · Enanta Pharmaceuticals, Inc
- Mesantoin · Novartis
- Mysoline · Bausch Health
- Dilantin · Pfizer
Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Localization-related epilepsy patent landscape — cliff calendar, originator estates, attackable patents
- Localization-related epilepsy treatment landscape brief
- Localization-related epilepsy treatment updates RSS
Frequently asked questions about Localization-related epilepsy
What drugs treat Localization-related epilepsy?
Tracked treatments include Phenytoin Sodium, Tegretol, Carbamazepin, Mesantoin, Mysoline, Dilantin.
What is the treatment for Localization-related epilepsy?
Standard treatment for Localization-related epilepsy includes Phenytoin Sodium, Tegretol, Carbamazepin, Mesantoin, Mysoline. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Localization-related epilepsy patent cliff · Localization-related epilepsy CI report
- Treatment: Phenytoin Sodium · Viatris
- Treatment: Tegretol · Novartis AG (originally Geigy)
- Treatment: Carbamazepin · Enanta Pharmaceuticals, Inc
- Treatment: Mesantoin · Novartis
- Treatment: Mysoline · Bausch Health
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing